Abatacept versus tocilizumab for the treatment of rheumatoid arthritis in TNF inhibitor inadequate responders: study protocol of the SUNSTAR randomised controlled open-label superiority trial

Abatacept versus tocilizumab for the treatment of rheumatoid arthritis in TNF inhibitor inadequate responders: study protocol of the SUNSTAR randomised controlled open-label superiority trial

Introduction Biological disease modifying antirheumatic drugs (bDMARDs) have a central role in the treatment of rheumatoid arthritis (RA). Tumour necrosis factor inhibitors (TNFis) are commonly used as first-line agents, while non-TNFis (tocilizumab, abatacept and rituximab) have shown to be non-inf...

Full description

Saved in:
Bibliographic Details
Main Authors: Bruno Fautrel, Pascal Richette, Christian Roux, Grégoire Cormier, Martin Soubrier, Xavier Mariette, Christophe Richez, Jacques-Eric Gottenberg, Hubert Marotte, Jacques Morel, Rene-Marc Flipo, Jerome Avouac, Athan Baillet, Gael Mouterde, Anne Tournadre, Marie-Elise Truchetet, Sebastien Ottaviani, Tristan Pascart, Thierry Lequerre, Elisabeth Gervais, Luca Semerano, André Basch, Edouard Pertuiset, Jean-Hugues Salmon, Eric Houvenagel, VÉRONIQUE BREUIL, Marie Vandecandelaere, Olivier Vittecocq, Isabelle Griffoul, Charlotte Jauffret, Vincent Ducoulombier, Laurène Norberciak, Jean-Guillaume Letarouilly, Slim Lassoued, Renaud Desbarbieux, Hélène Luraschi, Thibault Rabin, Gauthier Marchasson, Catherine Godart, Nicolas Taisne
Format: Article
Language:English
Published: BMJ Publishing Group 2025-06-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/15/6/e098298.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items